DSS, Dextran Sodium Sulfate ,葡聚糖硫酸钠,500g

¥14000
MP Biomedicals
2021-06-28 17:53

北京上元丰生物科技有限公司

我要认领
北京上元丰生物科技有限公司
王文娟
15110099293
wangwenjuandaxue@126.com
727018904
产品说明

联系人:王文娟

QQ/微信: 727018904

手机: 15110099293

电子邮件: 

CAS NUMBER:
9011-18-1
MOLECULAR WEIGHT:
36,000 - 50,000 Da
MDL NUMBER:
MFCD00081551

Dextran sulfate sodium salt, or DSS, is a synthetic sulfated branched polysaccharide derivative of dextran that has multiple uses in biomedical and clinical research (see table below). One important property of DSS is to triggers colitis in mice and rats when administered in drinking water. DSS binds to medium-chain-length fatty acids in the colon and induces intestinal inflammation. MP Premium Dextran Sulfate Sodium Salt (MW = 36,000–50,000) from MP Biomedicals is one of the most widely used product based on peer reviewed scientific publications. Over the past 15 years 3,000+ scientific publications have cited the use of our DSS.

Application Notes

Dextran sulfate sodium (DSS) is one of the most common and effective compounds used for inducing ulcerative colitis in animals. The DSS colitis model has also been used extensively to study colon cancer developing in relation to colonic inflammation, such as that occurring in patients with long-standing ulcerative colitis.

MP Biomedicals offers the gold standard of colitis model creation reagents - colitis grade dextran sulfate sodium salt (36,000-50,000) and colonic carcinogen azoxymethane (AOM).

Because of its high efficacy, MP Biomedical DSS is one of the most widely used DSS products in the scientific literature. Over the past 19 years more than 10,000 scientific publications have cited the use of MP Biomedicals’ DSS products and reported successful animal model establishment.

Usage Statement

Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.

Key Applications

Acute/ Chronic Ulcerative Colitis Model Induction, Chronic Colitis Associated Colon Cancer Model Induction